drugset / Trial / NCT06307795

A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06307795

Phase 1 Recruiting 63 enrolled Avistone Biotechnology Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.

Timeline

Start
2024-06-24
Primary completion
2027-04
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ANS014004 Small molecule

Indications

No indication recorded.